Log in with your email address username.


[Comment] Interleukin-17 inhibition in psoriatic arthritis

Psoriatic arthritis1 has struggled behind rheumatoid arthritis in terms of basic science, treatment, and national priorities. The disease is slightly less common than is rheumatoid arthritis, and the original series from Leeds, UK, suggested that psoriatic arthritis had a fairly benign outcome.2 More recently, it has become apparent that psoriatic arthritis can have an equivalently devastating effect on patient function and quality of life.3 However, important differences remain. Psoriatic arthritis is a heterogeneous disease with several musculoskeletal manifestations, and prominent extra-articular manifestations, such as psoriasis.